Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190 , November 2010

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study

  • M.A. Banerji

      Affiliations

    • SUNY Health Science Center, Brooklyn, NY, USA
    • ,
  • D. Purkayastha

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • B.H. Francis

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • Corresponding Author InformationCorresponding author at: Novartis Pharmaceuticals Corporation, One Health Plaza, Bldg. 501-Room 336, East Hanover, NJ 07936-1080, USA. Tel.: +1 862 7788337; fax: +1 862 7782345.

Received 11 March 2010 ,Revised 14 June 2010 ,Accepted 17 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0168-8227(10)00324-4

doi: 10.1016/j.diabres.2010.06.022

Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190 , November 2010

Article Tools

* Image Usage & Resolution